Alan Rauba, MD
Endocrinology, Diabetes & Metabolism · Jefferson City, MONPI 1568442267
Payments from drug & device makers
What this record shows
This record is dominated by speaking fees: $538,051 of the $593,720 with a category attached, or 90.6%. 53 manufacturers reported payments, led by Lilly USA, LLC at 49.0% of the total. Reporting peaked in 2019 at $169,245 and has fallen 59.9% since, to $67,917 in 2025. Among endocrinology, diabetes & metabolism clinicians in MO with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 1,562 payments — averaging $380.10 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Lilly USA, LLC$291K
- Novo Nordisk$213K
- AstraZeneca$70K
- Boehringer Ingelheim$14K
- Tandem Diabetes Care, Inc.$2K
- Amgen$876
- plus $4K from 47 others
What the payments were for
- Consulting fees$6,1961%
- Speaking & faculty fees$538,05191%
- Travel & lodging$31,5865%
- Food & beverage$17,7873%
- Education$990%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- MOUNJARO$142,411
- TRULICITY$108,349
- Ozempic$106,073
- FARXIGA$68,031
- RYBELSUS$63,127
- JARDIANCE$40,099
- Tresiba$20,060
- Xultophy 100/3.6$3,700
- t:slim X2 Insulin Pump with Control-IQ$1,800
How this compares
$593,720 in reported general payments places this provider in the 95th percentile of 182 endocrinology, diabetes & metabolism providers in Missouri.
See all endocrinology, diabetes & metabolism providers in Missouri →
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| OzempicSemaglutide | 585 | $836,776 |
| JardianceEmpagliflozin | 694 | $639,361 |
| FarxigaDapagliflozin Propanediol | 419 | $428,565 |
| TrulicityDulaglutide | 280 | $375,601 |
| MounjaroTirzepatide | 194 | $253,471 |
| Tresiba Flextouch U-200Insulin Degludec | 129 | $191,945 |
| JanuviaSitagliptin Phosphate | 150 | $125,659 |
| Toujeo Max SolostarInsulin Glargine,hum.Rec.Anlog | 102 | $109,919 |
| Humalog Kwikpen U-200Insulin Lispro | 13 | $58,972 |
| Xigduo XrDapaglifloz Propaned/Metformin | 34 | $38,098 |
| Bydureon BciseExenatide Microspheres | 30 | $33,514 |
| Toujeo SolostarInsulin Glargine,hum.Rec.Anlog | 45 | $32,037 |
| TradjentaLinagliptin | 36 | $30,242 |
| RybelsusSemaglutide | 19 | $27,992 |
| DescovyEmtricitabine/Tenofov Alafenam | 12 | $25,484 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Novo NordiskOzempic, Rybelsus | $212,682 | $864,769604 claims |
| Boehringer IngelheimJardiance, Tradjenta, Synjardy Xr | $13,758 | $690,988745 claims |
| Lilly USA, LLCTrulicity, Mounjaro, Humalog | $290,628 | $644,357534 claims |
| AstraZenecaFarxiga | $69,618 | $428,565419 claims |
| MerckJanuvia, Janumet Xr | $12 | $145,239175 claims |
| AmgenProlia | $876 | $21,68713 claims |
| Acella Pharmaceuticals, LLCNp Thyroid | $57 | $19,796227 claims |
| PfizerEliquis | $30 | $18,93020 claims |
| BayerKerendia | $495 | $18,02819 claims |
| AbbVieArmour Thyroid, Synthroid | $413 | $17,629240 claims |
| Amneal Pharmaceuticals LLCLevothyroxine Sodium | $48 | $7,765704 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 182 endocrinology, diabetes & metabolism providers in Missouri.
Other endocrinology, diabetes & metabolism in Jefferson City
- Christopher CaseJefferson City$121K
- Ralph DudaSpringfield$644K
- Karen Chang-ChenChesterfield$640K
- Jerome ThurmanSaint Charles$312K
- Janet McGillSaint Louis$212K
- Megan WoodSt. Louis$207K
- Ralph OiknineChesterfield$144K
- Jonben SvobodaSpringfield$142K
- James BonucchiSpringfield$128K
- Adam MaghrabiBlue Springs$120K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.